To Our Global Community:
In 2021, society made progress in recovering from a global pandemic while, at the same time, continuing to grapple with persistent and interdependent global health, economic, geopolitical and environmental challenges. We are living through a time when the risks to a peaceful, prosperous global future feel as urgent as ever. Against this backdrop, Johnson & Johnson sees a greater need for compassion, innovation and revitalization.
Guided by Our Credo—a set of timeless values—our 144,000 employees feel a deep responsibility to deliver on Our Purpose of blending heart, science and ingenuity to profoundly improve health for everyone, everywhere. To achieve this aspiration, we are focused on meaningful solutions, creating impact and collaboration.
In my first year as Chief Executive Officer, together with the Executive Committee and Board of Directors, we are charting our future to evolve and lead through an increasingly dynamic world. This includes announcing our intention to separate our Consumer Health business into a new publicly traded company and the creation of a new Johnson & Johnson with our Pharmaceutical and MedTech businesses to better serve patients and consumers, accelerate innovation, and unlock growth.
We also continued to deliver enduring impact by formalizing our environmental, social and governance (ESG) strategy, which frames our ambitions, informs our execution and creates accountability for our vision of the future. This is supported by our Health for Humanity 2025 Goals that we all stand behind.
Our ESG strategy is organized around three focus areas where we can achieve the greatest impact: championing global health equity, empowering our employees and advancing environmental health. This roadmap reflects our long-term goals to deliver value by helping patients and healthcare providers achieve better health outcomes, fostering rewarding opportunities for our employees and suppliers, protecting and strengthening communities, and providing profitable, sustainable growth for investors. All of this is underpinned by our commitment to accountability and innovation, as we conduct our business with integrity to continually earn the trust of those we serve and create value for all stakeholders.
Through innovative pharmaceutical therapies, medtech solutions and consumer health products, we aim to help patients and communities in the greatest need. We see unlimited possibilities in leveraging intelligent automation and data science to transform healthcare. We believe that digitization, robotics and cloud connectivity will result in greater collaboration across healthcare communities by facilitating sharing of real-world data and delivery of breakthrough medical care for all.
At Johnson & Johnson, this approach to innovation is our future and how we will improve our impact on the world.
In 2021, we made notable advances in our ESG performance and our Health for Humanity 2025 Goals, including:
- To drive global health equity, we provided our COVID-19 vaccine globally at a not-for-profit price and shipped 180 million doses of our single-shot COVID-19 vaccine to the African Union, COVAX and South Africa through advanced purchase agreements and country donations; we provided 731,000 nurses, midwives and community health workers with skills, tools and growth opportunities; as part of Our Race to Health Equity, we invested in culturally competent community care models to close racial health gaps, reaching 159,000 healthcare professionals and researchers in the U.S.; and we strengthened local economies by spending $5.22 billion with small and diverse suppliers, achieving a milestone in our accountable business practices.
- To drive future innovation, our R&D spend increased to $14.7 billion, the highest annual spend in our recent history.
- To further empower employees, we refreshed our Enterprise diversity, equity and inclusion strategy and increased global representation of women and ethnic, racially diverse employees at all levels of our business while reinforcing a culture of inclusion and belonging.
- To advance environmental health, in alignment with global climate change mitigation efforts, we signed the Race to Zero/Business Ambition for 1.5°C campaign, aiming to achieve net zero carbon emissions by 2045, as we further reduced our carbon footprint by 34%. And as part of our Healthy Lives Mission and as a signatory to the Ellen MacArthur Foundation’s New Plastics Economy Global Commitment, Consumer Health declared a commitment to reduce total annual use of virgin plastics in packaging weight by 25% by 2025.
We are making strong progress toward achieving our Health for Humanity 2025 Goals. Already, we have exceeded one target and are on track to deliver against the remaining 20 goals.
As we look to the future, 2022 will be another transformative year. Our Purpose has never been clearer, and our resolve has never been stronger. We are committed to doing our part, as individuals, as a team and as partners within the global healthcare ecosystem.
It is with an acknowledgment of the major tasks that lie ahead, together with our determination to succeed, that I invite you to read this Report to learn of our progress and discover what is yet to come.
Thank you for your interest.
Chief Executive Officer